| Document |
Document Title |
|
WO/2024/011294A1 |
The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers t...
|
|
WO/2024/003428A1 |
The present invention relates to quinone-derived compounds with leishmanicidal activity and to the use of same in the pharmaceutical industry, specifically in the field of parasitic diseases. The invention relates specifically to a compo...
|
|
WO/2024/003223A1 |
The present invention relates to a fucosylated saccharide, or a composition comprising a fucosylated saccharide, for use in preventing and/or treating a parasite infection in a subject, preferably cryptosporidiosis.
|
|
WO/2024/005032A1 |
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...
|
|
WO/2023/245258A1 |
This disclosure relates generally to the use of compounds that inhibit binding of Plasmodium cysteine-rich protective antigen (CyRPA) to glycans of cells that are susceptible to infection by Plasmodium pathogens, including glycans termin...
|
|
WO/2023/248871A1 |
Provided are a compound represented by formula (I), etc. (wherein: Z represents an oxygen atom, etc.; R1, R2, R3 and R4 each independently represent a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group; Y1 and Y2 each indep...
|
|
WO/2023/243678A1 |
The present invention provides a pyrazole compound represented by formula (1) or a salt thereof, and a novel bactericide containing same as an active ingredient, particularly, a bactericide for agricultural and horticultural use. In the ...
|
|
WO/2023/242070A1 |
The invention relates to phenylene diamine derivatives with certain pharmacological properties resulting from enhancement of epithelial barrier function and/or blocking bacterial translocation through the epithelial barrier. The compound...
|
|
WO/2023/242598A1 |
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
|
|
WO/2023/239811A1 |
Provided herein are Endochin-Like Quinolone (ELQ) compounds of Formula (I): or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions comprising them and methods for their use in treating or preventing parasit...
|
|
WO/2023/237795A1 |
The present invention relates to the use of an elatol compound for treating or preventing primary amebic meningoencephalitis (PAM) caused by Naegleria fowleri in a human or animal subject. The invention also relates to the pharmaceutical...
|
|
WO/2023/240045A1 |
Use of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), mavelertinib, as a treatment for giardiasis in humans, veterinary animals, and livestock is described. Mavelertinib demonstrates a high selectivity index f...
|
|
WO/2023/232123A1 |
Provided are a sesquiterpene polyketone compound, a pharmaceutical composition, and use thereof as an immunomodulator and in preventing and treating immune diseases. Biological activity assay shows that the sesquiterpene polyketone compo...
|
|
WO/2023/233413A1 |
Methods of inhibiting eIF4Gl binding to elFl, and inhibiting translation initiation are provided. Pharmaceutical compositions comprising inhibitors of eIF4Gl-eIFl binding and there use in treating disease are also provided.
|
|
WO/2023/235480A1 |
Provided herein are aryl hydantoin compounds having the structure of Formula (I) wherein X, R1, R2, R3, R4, and n are described herein. Also provided herein are compositions comprising compounds of Formula (I) and methods of using compou...
|
|
WO/2023/233200A1 |
This invention relates to a composition comprising: (a) a hydroalcoholic solution comprising a Quassia amara extract, wherein the solution comprises at least 80 %v/v of at least one alcohol, and (b) a vegetable oil. The invention also re...
|
|
WO/2023/228257A1 |
The present invention addresses the problem of providing a novel anti-cryptosporidium drug. The present invention provides an anti-cryptosporidium drug containing at least one selected from the group consisting of bufotalin, cinobufotali...
|
|
WO/2023/230217A1 |
Provided herein are antileishmanial compounds, compositions comprising the antileishmanial compounds, and use thereof.
|
|
WO/2023/221862A1 |
Provided are an anti-parasitic infection external pharmaceutical formulation , a preparation method therefor and use thereof. The external pharmaceutical formulation comprises a first active ingredient and an aldehyde compound, the first...
|
|
WO/2023/218194A1 |
The present invention concerns compounds suitable as RNA or DNA binders. RNA or DNA binders are useful in the treatment of various conditions, including those caused by microbial infection and cancer. The present invention concerns speci...
|
|
WO/2023/220281A1 |
The present disclosure provides feed additive compositions and related methods for the treatment and prevention of coinfection with Clostridium bacteria and Eimeria protozoa. The feed additive compositions herein can include a microbial ...
|
|
WO/2023/215819A2 |
Methods of reducing viability of a parasite in a subject involve administering an effective amount of an inhibitor of guanosine-5'-triphosphate cyclohydrolase I (GCH) to the subject. Methods of identifying an agent that reduces viability...
|
|
WO/2023/213998A1 |
The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antig...
|
|
WO/2023/209336A1 |
The invention relates to compounds or pharmaceutically acceptable salts thereof, compositions containing them, including combinations with at least one additional therapeutic agent, and their use in therapy, for example in the treatment ...
|
|
WO/2023/209250A1 |
The present disclosure relates to a compound of the formula (6) or (7); or a pharmaceutically acceptable salt, ester, solvate thereof, for use in medicine, in particular for the use in treatment and therapy of malaria and leishmaniasis. ...
|
|
WO/2023/211275A1 |
The present invention provides novel fusion polypeptides and compositions comprising the same. The fusion polypeptides are able to trigger and/or enhance an immune response against a peptide sequence of interest comprised therein and the...
|
|
WO/2023/205272A1 |
The present application provides compounds and methods for treating various diseases such as malaria and cancer.
|
|
WO/2023/205378A1 |
The natural product neurolenin D is isolated from Neurolaena lobata using continuous extraction, stirring over charcoal, flash column chromatography, and recrystallization. The secondary alcohol in this molecule is converted into a metha...
|
|
WO/2023/202336A1 |
Provided in the present invention are the uses of an HPK1 inhibitor in preparation of drugs for preventing and/or treating human diseases or symptoms caused by pathogen infection or related to pathogen infection, and in preparation of dr...
|
|
WO/2023/200009A1 |
The present disclosure provides an antiprotozoal agent targeting a transcription factor. The present disclosure provides a pyrrole-imidazole polyamide (PIPA) specifically binding to a binding region of a protozoa transcription factor.
|
|
WO/2023/200036A1 |
The present invention relates to microparticles containing moxidectin and a method for preparing same. Unlike conventional drugs for preventing heartworm disease, which have a short half-life and require daily or monthly administration, ...
|
|
WO/2023/200035A1 |
The present invention relates to microparticles containing moxidectin, and a preparation method thereof. Unlike conventional heartworm prevention drugs that have a short half-life and thus require daily or monthly administration, moxidec...
|
|
WO/2023/197079A1 |
Described herein is malarial immunogen or a variant thereof comprising at least a portion of the wild-type PfCSP amino acid sequence lacking a KQ motif. In aspects, the malarial immunogen is lacking a KQP motif. For example, the immunoge...
|
|
WO/2023/194388A1 |
The present invention relates to single-domain antibodies having a binding affinity for the antigen microneme protein 2 (MIC2) of Eimeria parasites; to fusion proteins comprising multimer components of the single-domain antibodies; and t...
|
|
WO/2023/194411A1 |
The present invention is in the field of therapeutic drugs to treat malaria. In particular, the invention provides oxo-azaheterocyclic derivatives for use in the treatment of malaria, for example drug-resistant malaria.
|
|
WO/2023/187607A1 |
The present disclosure is directed to compounds of Formula I and pharmaceutical compositions comprising thereof. Further, use of compounds and pharmaceutical compositions in medicine, particularly in inhibiting or reducing the formation ...
|
|
WO/2023/189602A1 |
A number of pest control agents have been used over the years. However, many of these pest control agents have various problems, for example, insufficient efficacy and limitation on the use thereof due to the occurrence of resistant pest...
|
|
WO/2023/187827A1 |
The present disclosure relates to a pharmaceutical composition to combat artemisinin resistance in malaria with the identification of Plasmodium falciparum (Pf) glutamine synthetase (GS) as a drug target. Pf Gs is important for maintaini...
|
|
WO/2023/190015A1 |
In the production of crops in agriculture, horticulture, etc., damages caused by pests, etc., are still significant, and it has been required to develop a new agricultural and horticultural pesticide due to factors such as the emergence ...
|
|
WO/2023/190286A1 |
A compound represented by formula (1) or a salt thereof, or an N-oxide thereof. [In formula (1), X1 represents an oxygen atom, a sulfur atom, NY1, or C(J5J6), n represents 0 or 1, J1-J4 each represent a hydrogen atom, a halogen atom, a (...
|
|
WO/2023/180964A1 |
The present invention relates to pyrazine amide derivative compounds, such as those according to formula (I) and compositions including said compounds, The invention also provides such pyrazine amide derivative compounds for use in the t...
|
|
WO/2023/170057A1 |
The present invention relates to a composition, an in ovo vaccine, and a composition for use as a vaccine against coccidiosis, which comprises Eimeria oocysts from a precocious attenuated strain of E. acervulina, and from at least one pr...
|
|
WO/2023/170183A1 |
The present invention relates to a combination of different components and its use, where the invention comprises as the basic component at least one organic acid and/or its salt, an iron component, Ceylon cinnamon and B-vitamins. The co...
|
|
WO/2023/169664A1 |
The present invention relates to a combination of different components and its use, where the invention comprises as the basic component at least one organic acid and/or its salt, an iron component, Ceylon cinnamon and B-vitamins. The co...
|
|
WO/2023/171665A1 |
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...
|
|
WO/2023/157880A1 |
[Problem] To provide a malaria vaccine which has an excellent preventative effect against infection and excellent effect of inhibiting malaria transmission, as compared to conventional malaria vaccines. [Solution] It was found that using...
|
|
WO/2023/154466A1 |
Arylbenzoisoxazole compounds of Formula (II), where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcohol...
|
|
WO/2023/154486A1 |
A composition, for use in controlling lice or their ova on an animal subject, comprises a reactive copolymer formed from two or more monomers and having a hydrophobic conditioning portion comprising a siloxane group, a reactive crosslink...
|
|
WO/2023/152042A1 |
A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, substituted in the 6-position by an arylphenyl or heteroarylphenyl moiety, being potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in h...
|
|
WO/2023/137529A1 |
The present invention relates to compounds which are active against parasitic infections, such as protozoan parasite infections (including flagellate parasite infections, ciliate parasite infections, amoeba parasite infections and apicom...
|
